A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522038-29-00

Enrollment

Registered

2026-06-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced, unresected (unresectable or medically inoperable or refuse surgery) Stage II-III NSCLC with KRAS G12C mutation

Brief summary

Progression-Free Survival (PFS)

Detailed description

Overall Survival (OS), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Objective Response Rate (ORR), Duration of Response (DOR), Distant Metastasis-Free Survival (DMFS), Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) (Items 29 & 30) Combined Score, Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Combined Score, Change from Baseline in Role Functioning (EORTC QLQ-C30 Items 6 & 7) Combined Score

Interventions

DRUGMK-1084

DRUGDURVALUMAB

DRUGPlacebo for MK-1084

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
Overall Survival (OS), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Objective Response Rate (ORR), Duration of Response (DOR), Distant Metastasis-Free Survival (DMFS), Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) (Items 29 & 30) Combined Score, Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Combined Score, Change from Baseline in Role Functioning (EORTC QLQ-C30 Items 6 & 7) Combined Score	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 13, 2026